Nevertheless, individuals who receive serplulimab, a PD-1 inhibitor, could potentially experience advantages from ASTRUM-005 (HR, 0.61, 0.33–1.13) (22), The mPFS and mOS data of this study are much better than those of previous studies were related to cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib regimen, and also related to the physical condition of enrolled patients and the underlying factors of metastatic tumor. The gene discussed is CTLA4; the disease is metastatic neoplasm.